Azathioprine Compared to Mycophenolate Mofetil Treatment in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis

被引：0
|
作者：
Shell, J. [1 ]
Kapralik, J. [2 ]
Jones, A. [3 ]
Farooqi, M. [2 ]
Beattie, K. [4 ]
Kolb, M. R. [2 ]
Cox, G. P. [2 ]
Scallan, C. J. [5 ]
Larche, M. J. [4 ]
Khalidi, N. A. [4 ]
Hambly, N. [5 ]
机构：
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] McMaster Univ, Div Respirol, Dept Med, Hamilton, ON, Canada
[3] McMaster Univ, Dept Hlth Res Methods, Hamilton, ON, Canada
[4] McMaster Univ, Div Rheumatol, Dept Med, Hamilton, ON, Canada
[5] McMaster Univ, Respirol, Hamilton, ON, Canada
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1915
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168
  • [2] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [3] Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis
    Schneider, Udo
    Siegert, Elise
    Glaser, Sven
    Kruger, Klaus
    Krause, Andreas
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (09): : 868 - 878
  • [4] Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil
    Takada, Toshinori
    Aoki, Ami
    Shima, Kenjiro
    Kikuchi, Toshiaki
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1242 - 1246
  • [5] Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease
    Lok, Stacey D.
    Wong, Alyson W.
    Khor, Yet H.
    Ryerson, Christopher J.
    Johannson, Kerri A.
    CHEST, 2022, 161 (06) : 1594 - 1597
  • [6] Malignancy Risk Associated with Mycophenolate Mofetil and Azathioprine in Patients with Fibrotic Interstitial Lung Disease
    Lok, S. D.
    Wong, A. W.
    Cox, G. P.
    Fell, C. D.
    Fisher, J. H.
    Gershon, A. S.
    Halayko, A. J.
    Hambly, N.
    Khalil, N.
    Kolb, M. R.
    Manganas, H.
    Marcoux, V
    Morisset, J.
    Assayag, D.
    Sadatsafavi, M.
    Shapera, S.
    To, T.
    Wilcox, P.
    Ryerson, C. J.
    Johannson, K. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [7] COST EFFECTIVENESS OF MOFETIL MYCOPHENOLATE COMPARED WITH CYCLOPHOSPHAMIDE FOR THE TREATMENT OF SYSTEMIC SCLEROSIS IN PATIENTS WITH DIFFUSE INTERSTITIAL PULMONARY DISEASE IN COLOMBIA
    Paola Saavedra, Ginna
    Bello Gualtero, Juan Manuel
    Quitian Reyes, Hoover
    Buitrago-Gutierrez, Giancarlo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S8 - S8
  • [8] Experience with azathioprine in systemic sclerosis associated with interstitial lung disease
    K. Dheda
    U. G. Lalloo
    B. Cassim
    G. M. Mody
    Clinical Rheumatology, 2004, 23 : 306 - 309
  • [9] Experience with azathioprine in systemic sclerosis associated with interstitial lung disease
    Dheda, K
    Lalloo, UG
    Cassim, B
    Mody, GM
    CLINICAL RHEUMATOLOGY, 2004, 23 (04) : 306 - 309
  • [10] Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis.
    Pham, Michael
    Griffing, W. Leroy
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S742 - S742
12345